HEADER VIRAL PROTEIN 28-MAR-07 2UXE TITLE THE STRUCTURE OF VACCINIA VIRUS N1 COMPND MOL_ID: 1; COMPND 2 MOLECULE: HYPOTHETICAL PROTEIN; COMPND 3 CHAIN: A, B, C, D, E, F; COMPND 4 SYNONYM: VACV-DUKE-037, VIROKINE, VACV026, N1L; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: VACCINIA VIRUS; SOURCE 3 ORGANISM_TAXID: 10245; SOURCE 4 STRAIN: WESTERN RESERVE; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 7 EXPRESSION_SYSTEM_STRAIN: B834; SOURCE 8 EXPRESSION_SYSTEM_VECTOR: PET24A KEYWDS VIRAL PROTEIN, BCL-LIKE PROTEIN, HYPOTHETICAL PROTEIN, KEYWDS 2 VIRAL PROTEIN APOPTOSIS, VACCINIA VIRUS, VIRULENCE FACTOR EXPDTA X-RAY DIFFRACTION AUTHOR S.COORAY,M.W.BAHAR,N.G.A.ABRESCIA,C.E.MCVEY,N.W.BARTLETT, AUTHOR 2 R.A.-J.CHEN,D.I.STUART,J.M.GRIMES,G.L.SMITH REVDAT 2 24-FEB-09 2UXE 1 VERSN REVDAT 1 22-MAY-07 2UXE 0 JRNL AUTH S.COORAY,M.W.BAHAR,N.G.A.ABRESCIA,C.E.MCVEY, JRNL AUTH 2 N.W.BARTLETT,R.A.-J.CHEN,D.I.STUART,J.M.GRIMES, JRNL AUTH 3 G.L.SMITH JRNL TITL FUNCTIONAL AND STRUCTURAL STUDIES OF THE VACCINIA JRNL TITL 2 VIRUS VIRULENCE FACTOR N1 REVEAL A BCL-2-LIKE JRNL TITL 3 ANTI- APOPTOTIC PROTEIN JRNL REF J.GEN.VIROL. V. 88 1656 2007 JRNL REFN ISSN 0022-1317 JRNL PMID 17485524 JRNL DOI 10.1099/VIR.0.82772-0 REMARK 2 REMARK 2 RESOLUTION. 2.9 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS 1.1 REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES, PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.9 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 30 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.0 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 10000 REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 100.0 REMARK 3 NUMBER OF REFLECTIONS : 22413 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.2372 REMARK 3 FREE R VALUE : 0.2435 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 4.9 REMARK 3 FREE R VALUE TEST SET COUNT : 1094 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 21 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.9 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.95 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 100 REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1000 REMARK 3 BIN R VALUE (WORKING SET) : 0.5279 REMARK 3 BIN FREE R VALUE : 0.4360 REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 4.9 REMARK 3 BIN FREE R VALUE TEST SET COUNT : 56 REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 899 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 56 REMARK 3 SOLVENT ATOMS : 0 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 75 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -11.359 REMARK 3 B22 (A**2) : 12.159 REMARK 3 B33 (A**2) : -0.800 REMARK 3 B12 (A**2) : 0.000 REMARK 3 B13 (A**2) : -21.454 REMARK 3 B23 (A**2) : 0.000 REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.014 REMARK 3 BOND ANGLES (DEGREES) : 1.6 REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : 5.4 ; 5 REMARK 3 MAIN-CHAIN ANGLE (A**2) : 7.6 ; 8 REMARK 3 SIDE-CHAIN BOND (A**2) : 11.2 ; 7 REMARK 3 SIDE-CHAIN ANGLE (A**2) : 15.4 ; 10 REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : FLAT MODEL REMARK 3 KSOL : 0.31 REMARK 3 BSOL : 70 REMARK 3 REMARK 3 NCS MODEL : CONSTRAINTS REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM REMARK 3 PARAMETER FILE 2 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 TOPOLOGY FILE 2 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: NCS CONSTRAINTS USED THROUGHOUT REMARK 3 REFINEMENT REMARK 4 REMARK 4 2UXE COMPLIES WITH FORMAT V. 3.15, 01-DEC-08 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 28-MAR-07. REMARK 100 THE PDBE ID CODE IS EBI-32085. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : 6.20 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : ID23-1 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9794 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 22319 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.900 REMARK 200 RESOLUTION RANGE LOW (A) : 30.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -5.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 100.0 REMARK 200 DATA REDUNDANCY : 11.900 REMARK 200 R MERGE (I) : 0.14000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 17.9000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.90 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 3.00 REMARK 200 COMPLETENESS FOR SHELL (%) : 100.0 REMARK 200 DATA REDUNDANCY IN SHELL : 11.40 REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 1.800 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MAD REMARK 200 SOFTWARE USED: SOLVE REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 61.21 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.2 M NA/K PHOSPHATE, 0.2 M REMARK 280 NACL AND 10% PEG 8000, PH 6.2 REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 54.49950 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 GENERATING THE BIOMOLECULE REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: B, E REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: D, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 40 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 40 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN C, CYS 40 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN D, CYS 40 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN E, CYS 40 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN F, CYS 40 TO SER REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 GLU A 116 REMARK 465 LYS A 117 REMARK 465 GLU B 116 REMARK 465 LYS B 117 REMARK 465 GLU C 116 REMARK 465 LYS C 117 REMARK 465 GLU D 116 REMARK 465 LYS D 117 REMARK 465 GLU E 116 REMARK 465 LYS E 117 REMARK 465 GLU F 116 REMARK 465 LYS F 117 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLY A 115 CA C O REMARK 470 GLY B 115 CA C O REMARK 470 GLY C 115 CA C O REMARK 470 GLY D 115 CA C O REMARK 470 GLY E 115 CA C O REMARK 470 GLY F 115 CA C O REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 REMARK 500 NE2 GLN A 17 OE1 GLN D 17 1554 1.29 REMARK 500 OE1 GLN D 17 NE2 GLN A 17 1544 1.29 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 ASN A 15 16.31 58.08 REMARK 500 ASP A 22 -16.61 -48.34 REMARK 500 ASN B 15 16.30 58.11 REMARK 500 ASP B 22 -16.61 -48.39 REMARK 500 ASN C 15 16.37 58.04 REMARK 500 ASP C 22 -16.50 -48.42 REMARK 500 ASN D 15 16.28 58.10 REMARK 500 ASP D 22 -16.63 -48.35 REMARK 500 ASN E 15 16.41 58.03 REMARK 500 ASP E 22 -16.67 -48.31 REMARK 500 ASN F 15 16.27 58.12 REMARK 500 ASP F 22 -16.62 -48.35 REMARK 500 REMARK 500 REMARK: NULL REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2I39 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF VACCINIA VIRUS N1L REMARK 900 PROTEIN REMARK 999 REMARK 999 SEQUENCE REMARK 999 CYS 40 WAS MUTATED TO SER SEMET WAS INCORPORATED IN PLACE REMARK 999 OF MET FO R PHASING DBREF 2UXE A 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 DBREF 2UXE B 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 DBREF 2UXE C 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 DBREF 2UXE D 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 DBREF 2UXE E 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 DBREF 2UXE F 1 117 UNP Q49PX0 Q49PX0_9POXV 1 117 SEQADV 2UXE SER A 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQADV 2UXE SER B 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQADV 2UXE SER C 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQADV 2UXE SER D 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQADV 2UXE SER E 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQADV 2UXE SER F 40 UNP Q49PX0 CYS 40 ENGINEERED MUTATION SEQRES 1 A 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 A 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 A 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 A 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 A 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 A 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 A 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 A 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 A 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS SEQRES 1 B 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 B 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 B 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 B 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 B 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 B 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 B 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 B 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 B 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS SEQRES 1 C 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 C 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 C 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 C 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 C 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 C 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 C 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 C 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 C 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS SEQRES 1 D 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 D 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 D 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 D 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 D 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 D 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 D 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 D 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 D 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS SEQRES 1 E 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 E 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 E 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 E 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 E 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 E 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 E 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 E 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 E 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS SEQRES 1 F 117 MSE ARG THR LEU LEU ILE ARG TYR ILE LEU TRP ARG ASN SEQRES 2 F 117 ASP ASN ASP GLN THR TYR TYR ASN ASP ASP PHE LYS LYS SEQRES 3 F 117 LEU MSE LEU LEU ASP GLU LEU VAL ASP ASP GLY ASP VAL SEQRES 4 F 117 SER THR LEU ILE LYS ASN MSE ARG MSE THR LEU SER ASP SEQRES 5 F 117 GLY PRO LEU LEU ASP ARG LEU ASN GLN PRO VAL ASN ASN SEQRES 6 F 117 ILE GLU ASP ALA LYS ARG MSE ILE ALA ILE SER ALA LYS SEQRES 7 F 117 VAL ALA ARG ASP ILE GLY GLU ARG SER GLU ILE ARG TRP SEQRES 8 F 117 GLU GLU SER PHE THR ILE LEU PHE ARG MSE ILE GLU THR SEQRES 9 F 117 TYR PHE ASP ASP LEU MSE ILE ASP LEU TYR GLY GLU LYS MODRES 2UXE MSE A 1 MET SELENOMETHIONINE MODRES 2UXE MSE A 28 MET SELENOMETHIONINE MODRES 2UXE MSE A 46 MET SELENOMETHIONINE MODRES 2UXE MSE A 48 MET SELENOMETHIONINE MODRES 2UXE MSE A 72 MET SELENOMETHIONINE MODRES 2UXE MSE A 101 MET SELENOMETHIONINE MODRES 2UXE MSE A 110 MET SELENOMETHIONINE MODRES 2UXE MSE B 1 MET SELENOMETHIONINE MODRES 2UXE MSE B 28 MET SELENOMETHIONINE MODRES 2UXE MSE B 46 MET SELENOMETHIONINE MODRES 2UXE MSE B 48 MET SELENOMETHIONINE MODRES 2UXE MSE B 72 MET SELENOMETHIONINE MODRES 2UXE MSE B 101 MET SELENOMETHIONINE MODRES 2UXE MSE B 110 MET SELENOMETHIONINE MODRES 2UXE MSE C 1 MET SELENOMETHIONINE MODRES 2UXE MSE C 28 MET SELENOMETHIONINE MODRES 2UXE MSE C 46 MET SELENOMETHIONINE MODRES 2UXE MSE C 48 MET SELENOMETHIONINE MODRES 2UXE MSE C 72 MET SELENOMETHIONINE MODRES 2UXE MSE C 101 MET SELENOMETHIONINE MODRES 2UXE MSE C 110 MET SELENOMETHIONINE MODRES 2UXE MSE D 1 MET SELENOMETHIONINE MODRES 2UXE MSE D 28 MET SELENOMETHIONINE MODRES 2UXE MSE D 46 MET SELENOMETHIONINE MODRES 2UXE MSE D 48 MET SELENOMETHIONINE MODRES 2UXE MSE D 72 MET SELENOMETHIONINE MODRES 2UXE MSE D 101 MET SELENOMETHIONINE MODRES 2UXE MSE D 110 MET SELENOMETHIONINE MODRES 2UXE MSE E 1 MET SELENOMETHIONINE MODRES 2UXE MSE E 28 MET SELENOMETHIONINE MODRES 2UXE MSE E 46 MET SELENOMETHIONINE MODRES 2UXE MSE E 48 MET SELENOMETHIONINE MODRES 2UXE MSE E 72 MET SELENOMETHIONINE MODRES 2UXE MSE E 101 MET SELENOMETHIONINE MODRES 2UXE MSE E 110 MET SELENOMETHIONINE MODRES 2UXE MSE F 1 MET SELENOMETHIONINE MODRES 2UXE MSE F 28 MET SELENOMETHIONINE MODRES 2UXE MSE F 46 MET SELENOMETHIONINE MODRES 2UXE MSE F 48 MET SELENOMETHIONINE MODRES 2UXE MSE F 72 MET SELENOMETHIONINE MODRES 2UXE MSE F 101 MET SELENOMETHIONINE MODRES 2UXE MSE F 110 MET SELENOMETHIONINE HET MSE A 1 8 HET MSE A 28 8 HET MSE A 46 8 HET MSE A 48 8 HET MSE A 72 8 HET MSE A 101 8 HET MSE A 110 8 HET MSE B 1 8 HET MSE B 28 8 HET MSE B 46 8 HET MSE B 48 8 HET MSE B 72 8 HET MSE B 101 8 HET MSE B 110 8 HET MSE C 1 8 HET MSE C 28 8 HET MSE C 46 8 HET MSE C 48 8 HET MSE C 72 8 HET MSE C 101 8 HET MSE C 110 8 HET MSE D 1 8 HET MSE D 28 8 HET MSE D 46 8 HET MSE D 48 8 HET MSE D 72 8 HET MSE D 101 8 HET MSE D 110 8 HET MSE E 1 8 HET MSE E 28 8 HET MSE E 46 8 HET MSE E 48 8 HET MSE E 72 8 HET MSE E 101 8 HET MSE E 110 8 HET MSE F 1 8 HET MSE F 28 8 HET MSE F 46 8 HET MSE F 48 8 HET MSE F 72 8 HET MSE F 101 8 HET MSE F 110 8 HETNAM MSE SELENOMETHIONINE FORMUL 1 MSE 42(C5 H11 N O2 SE) HELIX 1 1 MSE A 1 ASN A 15 1 15 HELIX 2 2 ASP A 16 TYR A 20 5 5 HELIX 3 3 ASP A 22 LEU A 30 1 9 HELIX 4 4 ASP A 31 VAL A 34 5 4 HELIX 5 5 ASP A 35 LEU A 50 1 16 HELIX 6 6 ASP A 52 ASN A 60 1 9 HELIX 7 7 ASN A 65 GLY A 84 1 20 HELIX 8 8 ARG A 90 GLU A 103 1 14 HELIX 9 9 TYR A 105 TYR A 114 1 10 LINK C MSE A 1 N ARG A 2 1555 1555 1.33 LINK C LEU A 27 N MSE A 28 1555 1555 1.33 LINK C MSE A 28 N LEU A 29 1555 1555 1.33 LINK C ASN A 45 N MSE A 46 1555 1555 1.32 LINK C MSE A 46 N ARG A 47 1555 1555 1.32 LINK C ARG A 47 N MSE A 48 1555 1555 1.33 LINK C MSE A 48 N THR A 49 1555 1555 1.32 LINK C ARG A 71 N MSE A 72 1555 1555 1.32 LINK C MSE A 72 N ILE A 73 1555 1555 1.33 LINK C ARG A 100 N MSE A 101 1555 1555 1.33 LINK C MSE A 101 N ILE A 102 1555 1555 1.33 LINK C LEU A 109 N MSE A 110 1555 1555 1.33 LINK C MSE A 110 N ILE A 111 1555 1555 1.32 LINK C MSE B 1 N ARG B 2 1555 1555 1.33 LINK C LEU B 27 N MSE B 28 1555 1555 1.33 LINK C MSE B 28 N LEU B 29 1555 1555 1.33 LINK C ASN B 45 N MSE B 46 1555 1555 1.32 LINK C MSE B 46 N ARG B 47 1555 1555 1.32 LINK C ARG B 47 N MSE B 48 1555 1555 1.33 LINK C MSE B 48 N THR B 49 1555 1555 1.32 LINK C ARG B 71 N MSE B 72 1555 1555 1.32 LINK C MSE B 72 N ILE B 73 1555 1555 1.33 LINK C ARG B 100 N MSE B 101 1555 1555 1.33 LINK C MSE B 101 N ILE B 102 1555 1555 1.33 LINK C LEU B 109 N MSE B 110 1555 1555 1.33 LINK C MSE B 110 N ILE B 111 1555 1555 1.32 LINK C MSE C 1 N ARG C 2 1555 1555 1.33 LINK C LEU C 27 N MSE C 28 1555 1555 1.33 LINK C MSE C 28 N LEU C 29 1555 1555 1.33 LINK C ASN C 45 N MSE C 46 1555 1555 1.32 LINK C MSE C 46 N ARG C 47 1555 1555 1.32 LINK C ARG C 47 N MSE C 48 1555 1555 1.33 LINK C MSE C 48 N THR C 49 1555 1555 1.32 LINK C ARG C 71 N MSE C 72 1555 1555 1.32 LINK C MSE C 72 N ILE C 73 1555 1555 1.33 LINK C ARG C 100 N MSE C 101 1555 1555 1.33 LINK C MSE C 101 N ILE C 102 1555 1555 1.33 LINK C LEU C 109 N MSE C 110 1555 1555 1.33 LINK C MSE C 110 N ILE C 111 1555 1555 1.32 LINK C MSE D 1 N ARG D 2 1555 1555 1.33 LINK C LEU D 27 N MSE D 28 1555 1555 1.33 LINK C MSE D 28 N LEU D 29 1555 1555 1.33 LINK C ASN D 45 N MSE D 46 1555 1555 1.32 LINK C MSE D 46 N ARG D 47 1555 1555 1.32 LINK C ARG D 47 N MSE D 48 1555 1555 1.33 LINK C MSE D 48 N THR D 49 1555 1555 1.32 LINK C ARG D 71 N MSE D 72 1555 1555 1.32 LINK C MSE D 72 N ILE D 73 1555 1555 1.33 LINK C ARG D 100 N MSE D 101 1555 1555 1.33 LINK C MSE D 101 N ILE D 102 1555 1555 1.33 LINK C LEU D 109 N MSE D 110 1555 1555 1.33 LINK C MSE D 110 N ILE D 111 1555 1555 1.32 LINK C MSE E 1 N ARG E 2 1555 1555 1.33 LINK C LEU E 27 N MSE E 28 1555 1555 1.33 LINK C MSE E 28 N LEU E 29 1555 1555 1.33 LINK C ASN E 45 N MSE E 46 1555 1555 1.32 LINK C MSE E 46 N ARG E 47 1555 1555 1.32 LINK C ARG E 47 N MSE E 48 1555 1555 1.33 LINK C MSE E 48 N THR E 49 1555 1555 1.32 LINK C ARG E 71 N MSE E 72 1555 1555 1.32 LINK C MSE E 72 N ILE E 73 1555 1555 1.33 LINK C ARG E 100 N MSE E 101 1555 1555 1.33 LINK C MSE E 101 N ILE E 102 1555 1555 1.33 LINK C LEU E 109 N MSE E 110 1555 1555 1.33 LINK C MSE E 110 N ILE E 111 1555 1555 1.32 LINK C MSE F 1 N ARG F 2 1555 1555 1.33 LINK C LEU F 27 N MSE F 28 1555 1555 1.33 LINK C MSE F 28 N LEU F 29 1555 1555 1.33 LINK C ASN F 45 N MSE F 46 1555 1555 1.32 LINK C MSE F 46 N ARG F 47 1555 1555 1.32 LINK C ARG F 47 N MSE F 48 1555 1555 1.33 LINK C MSE F 48 N THR F 49 1555 1555 1.32 LINK C ARG F 71 N MSE F 72 1555 1555 1.32 LINK C MSE F 72 N ILE F 73 1555 1555 1.33 LINK C ARG F 100 N MSE F 101 1555 1555 1.33 LINK C MSE F 101 N ILE F 102 1555 1555 1.33 LINK C LEU F 109 N MSE F 110 1555 1555 1.33 LINK C MSE F 110 N ILE F 111 1555 1555 1.32 CRYST1 71.682 108.999 70.088 90.00 110.58 90.00 P 1 21 1 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.013951 0.000000 0.005238 0.00000 SCALE2 0.000000 0.009174 0.000000 0.00000 SCALE3 0.000000 0.000000 0.015240 0.00000 HETATM 1 N MSE A 1 -11.788 -74.822 -50.575 1.00 78.95 N HETATM 2 CA MSE A 1 -11.228 -74.847 -49.205 1.00 77.39 C HETATM 3 C MSE A 1 -9.821 -75.410 -49.067 1.00 77.94 C HETATM 4 O MSE A 1 -8.981 -74.849 -48.342 1.00 70.95 O HETATM 5 CB MSE A 1 -12.144 -75.649 -48.305 1.00 82.73 C HETATM 6 CG MSE A 1 -13.331 -74.871 -47.840 1.00109.02 C HETATM 7 SE MSE A 1 -12.825 -73.413 -46.670 1.00130.04 SE HETATM 8 CE MSE A 1 -12.780 -74.397 -45.001 1.00111.92 C